The way SARS-CoV-2 mutates in immunocompromised patients to escape Paxlovid could help chemists design better drugs that are more difficult for the virus to sidestep.
Columbia researchers have found why babies are susceptible to repeated bouts of common respiratory infections—but also have a unique weapon to fight off new pathogens that healthy adults lack.
Patients with mpox who were treated with the antiviral drug tecovirimat had similar outcomes regardless of HIV status, find researchers at Columbia University and Weill Cornell Medicine.
A trial of convalescent plasma for adults hospitalized with severe COVID-19 found that mortality at 28 days in the treatment arm was half the rate seen in the control arm (12.6% vs. 24.6%).
The post-COVID Community Mental Health Project aims to promote wellness and increase access to behavioral health services in underserved New York City neighborhoods.
A significant level of symptoms of depression, anxiety, and post-traumatic stress may follow COVID-19 independent of any previous psychiatric diagnoses, a new Mailman study finds.
A new study is drawing the most detailed picture yet of SARS-CoV-2 infection in the lung revealing mechanisms that cause lethal COVID-19 and how COVID-19 differs from other infectious diseases.
A Columbia neuroscientist and psychiatrist is peering into brain cells for clues that may explain how COVID-19 can lead to depression, anxiety, psychosis, and suicide.
Mailman's ICAP program is well-known for its efforts in fighting HIV, malaria, and TB around the world, but they're also busy in the fight against COVID-19 in nearby Harlem and Bronx neighborhoods.